PCRX
Pacira BioSciences, Inc.
NASDAQ · USHealthcareDrug Manufacturers - Specialty & Generic
$25.35-1.02%
Price as of Jul 20, 2026
PCRX profitability
Pacira BioSciences, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 79.3%
- EBITDA margin
- 16.1%
- EBIT margin
- 3.1%
- Net margin
- 0.7%
- Free cash flow margin
- 18.1%
Returns
- Return on equity
- 0.8%
- Return on assets
- 0.4%
- Return on invested capital
- 2.1%
- Asset turnover
- 0.59x
Cash efficiency
- Cash from operations
- $142.2M
- Cash per share
- $5.14
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.